Hutchmed has reported positive data from the Phase III FRUTIGA study of fruquintinib to treat advanced gastric cancer or gastroesophageal junction (GEJ) adenocarcinoma.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,